Omega-3-acid ethyl esters 90 (Lotriga)
Small molecule
Also known as TAK-085
Evidence outlook
Approved: Hyperlipidemia (JP)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
Also approved (1)
- Hyperlipidemia
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01350973 NCT01350973 · Hypertriglyceridemia The 611-participant study was randomized, quadruple-blinded, and actively controlled with EPA-E. Its primary triglyceride endpoint was mixed: the 4 g dose was significantly better than EPA-E, but the 2 g dose was not, and triglyceride change is a surrogate laboratory measure rather than a direct clinical outcome. Registry: NCT01350973 | 3 | Percent Change From Baseline in Triglyceride Level at the Final Visit (Baseline and 12 weeks) 2010-12 | Percent Change From Baseline in Triglyceride Level at the Final Visit (Baseline and 12 weeks): TAK-085 2 g -10.93% (Standard Error -14.161 to -7.7062) | TAK-085 4 g -22.65% (Standard Error -25.8436 to -19.4655) vs EPA-E 1.8 g -11.3% (Standard Error -14.6014 to -7.9998) | Partial signal | link ↗ |
View 1 more trial
NCT01350999 NCT01350999 · Hypertriglyceridemia This randomized, active-controlled Phase 3 study compared two doses of omega-3-acid ethyl esters 90 (TAK-085 2 g and 4 g daily) against EPA-E 1.8 g daily in 503 adults with hypertriglyceridemia over 52 weeks, but it was open-label rather than blinded. The primary endpoints were safety outcomes - counts of treatment-emergent adverse events and abnormal lab/ECG findings - reported per arm with no statistical comparisons, and these counts were similar across groups. Because the primary comparison lacks reported significance testing and the efficacy endpoint (triglyceride change) was secondary, the evidence is moderate. Registry: NCT01350999 | 3 | Number of Participants With Treatment Emergent Adverse Events (TEAEs) (52 Weeks); Number of Participants With TEAEs Associated With Abnormal Changes in Vital Signs (52 Weeks); Number of Participants With TEAEs Associated With Abnormal Changes in Body Weight (52 Weeks); Number of Participants With Clinically Significant Findings in Electrocardiogram After Study Drug Administration (52 Weeks); Number of Participants With TEAEs Categorized Into Investigations System Organ Class (SOC) Related to Chemistry, Hematology or Urinalysis (52 Weeks) 2011-01 | Number of Participants With Treatment Emergent Adverse Events (TEAEs) (52 Weeks): TAK-085 2 g 106 participants | TAK-085 4 g 110 participants | EPA-E 1.8 g 109 participants | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 4 (2)
What this study did
What this study did
Competitive landscape
Other Omega-3 fatty acid (EPA) drugs
Icosapent Ethyl. Compare all 2 Omega-3 fatty acid (EPA) drugs
1 other tracked programme targets this mechanism, 1 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Omega-3-Acid Ethyl Esters 90 (Lotriga): this drug | Phase 3 | Small molecule | Omega-3 fatty acid (EPA) | Partial signal | NCT01350973: Percent Change From Baseline in Triglyceride Level at the Final Visit (Baseline and 12 weeks): TAK-085 2 g -10.93% (Standard Error -14.161 to -7.7062) | TAK-085 4 g -22.65% (Standard Error -25.8436 to -19.4655) vs EPA-E 1.8 g -11.3% (Standard Error -14.6014 to -7.9998) | |
| Icosapent Ethyl (Vascepa) | Approved(overall) | Small molecule | Omega-3 fatty acid (EPA) | Reliable signal | NCT01492361: Composite of CV Death, Nonfatal MI (Including Silent MI), Nonfatal Stroke, Coronary Revascularization, or Unstable Angina Determined to be Caused by Myocardial Ischemia by Invasive / Non-invasive Testing and Requiring Emergent Hospitalization. (Total follow-up time of up to approximately 6 years.): AMR101 705/4089 vs Placebo 901/4090 NCT01047683: Difference Between AMR101 (Ethyl Icosapentate) and Placebo Treatment Groups in Triglyceride Lowering Effect (baseline and 12 weeks): AMR101 (Ethyl Icosapentate) - 2 g/Day -7 Percent change from baseline (IQR -30.1 to 18.6) | AMR101 (Ethyl Icosapentate) - 4 g/Day -26.6 Percent change from baseline (IQR -41.1 to 0) vs Placebo 9.7 Percent change from baseline (IQR -19.2 to 42.3) |
Upcoming events
No upcoming readouts on record for this asset.